Amgen challenges Alexion Pharma blood disorder treatment Soliris in US patent court Medical Dialogues Bureau2 Sep 2019 4:00 AM GMTThe IPR is seeking to invalidate new patents covering the composition of the main ingredient of Soliris, eculizumab, its formulation, and its use to...